Peripheral Blood Circulatory Tumour Cells Enumeration as A Non-Invasive Biomarker in Breast Cancer Diagnosis: A Case-Control Study
DOI:
https://doi.org/10.63682/jns.v14i25S.6731Keywords:
Breast cancer, circulating tumour cells, circulating tumour DNA, Liquid biopsy, OncologyAbstract
Aim and Background: Breast cancer is one of the most prevalent malignancy among women worldwide, and its early detection remains a challenge. Circulating tumour cells (CTCs) are emerging as promising biomarkers for the diagnosis, prognosis, and monitoring of cancer. This study aims to assess the diagnostic performance of CK-positive and HER2-positive CTCs in breast cancer patients and healthy controls.
Methods: This prospective case-control study involved 60 breast cancer patients (cases) and 60 age-matched healthy individuals (controls). Peripheral blood samples were collected prior to any oncological intervention. CTCs were isolated using Ficoll density gradient centrifugation and identified by flow cytometry, using cytokeratin (CK), CD45, and HER2 markers. Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) were performed to assess hormone receptor status (ER, PR, and HER2) in CTCs. All statistical analyses were performed using SPSS 14 software.
Results: Circulating tumour cells (CTCs) were detected in 85% of breast cancer patients, with cytokeratin-positive (CK+) CTCs showing high specificity and sensitivity for breast cancer detection (AUC = 1.000). Mann-Whitney U test results indicated significant differences in CTC counts between breast cancer patients and controls (p < 0.001 for both CK and HER2). In HER2-positive breast cancer, the expression of the HER2 marker demonstrated a 100% negative predictive value (NPV) and positive predictive value (PPV), along with a sensitivity of 51.67% and an area under the curve (AUC) of 0.758 for differentiation.
Conclusion: Our study results support the clinical utility of CTCs as non-invasive biomarkers for breast cancer detection and characterisation. Applications of liquid biopsy in precision oncology is valuable, and further large-scale validation studies are warranted to enhance the clinical implementation of CTC analysis in breast cancer management
Downloads
Metrics
References
Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.
Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Obser-Vatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2020. [(accessed on 9 July 2021)]. Available online: https://gco.iarc.fr/today.
Ginsburg O., Bray F., Coleman M., Vanderpuye V., Eniu A., Kotha S.R., Sarker M., Huong T.T., Allemani C., Dvaladze A., et al. The global burden of women’s cancers: A grand challenge in global health. Lancet. 2016;389:847–860. doi: 10.1016/S0140-6736(16)31392-7.
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287
Mehrotra R, Yadav K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022 Mar 24;13(3):209-218. doi: 10.5306/wjco.v13.i3.209. PMID: 35433294; PMCID: PMC8966510. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010 Oct;34(10):2308-24. doi: 10.1007/s00268-010-0683-1. PMID: 20607258; PMCID: PMC2936680.
Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010 Oct;34(10):2308-24. doi: 10.1007/s00268-010-0683-1. PMID: 20607258; PMCID: PMC2936680.
Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017 Aug;13(4):289-295.doi: 10.1111/ajco.12661.Epub 2017 Feb 9. PMID: 28181405.
Siddiqui B, Ahmed S, Sinha D, Sharma AVL. Molecular Classification of Breast Carcinoma in a Tertiary Hospital of India: the Recent Trends. Indian J Surg Oncol.2023 Mar;14(1):176-180. doi: 10.1007/s13193-022-01647-y. Epub 2022 Sep 16. PMID: 36891434; PMCID: PMC9986149.
Bhattacharyya GS, Doval DC, Desai CJ, Chaturvedi H, Sharma S, Somashekhar SP. Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective. JCO Glob Oncol. 2020 Jun;6:789-798. doi: 10.1200/GO.20.00033. PMID: 32511068; PMCID: PMC7328098.
Duggan C., Dvaladze A., Rositch A.F., Ginsburg O., Yip C., Horton S., Rodriguez R.C., Eniu A., Mutebi M., Bourque J., et al. The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview. Cancer. 2020;126:2339–2352. doi: 10.1002/cncr.32891.
Alix-Panabières, C., Marchetti, D. & Lang, J.E. Liquid biopsy: from concept to clinical application. Sci Rep 13, 21685 (2023). https://doi.org/10.1038/s41598-023-48501-x
Morgan T. M. (2019). Liquid biopsy: Where did it come from, what is it, and where is it going?. Investigative and clinical urology, 60(3), 139–141. https://doi.org/10.4111/icu.2019.60.3.139
Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, et al. Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature. Mol Cancer Res. 2018;16:643–654. doi: 10.1158/1541-7786.MCR-17-0539
Andreou, M., Vartholomatos, E., Harissis, H., Markopoulos, G. S., & Alexiou, G. A. (2019). Past, present and future of flow cytometry in breast cancer–a systematic review. EJIFCC, 30(4), 423.
Zhu, C., Xu, J., Sun, J., Cui, S., Sun, Y., Yu, T., Wang, C., Wang, T., Wu, Y., Ju, F., Yao, J., Liu, K., Zhang, W., & Guan, X. (2022). Circulating Tumor Cells and Breast Cancer Metastasis: From Enumeration to Somatic Mutational Profile. Journal of clinical medicine, 11(20), 6067. https://doi.org/10.3390/jcm11206067
Vijay, Jahnvi; Kumar, B Deepak; Murthy, V Srinivasa. Detection of Circulating Tumor Cells by Cell Block Technique in Malignant Tumors. Journal of Cytology 41(1):p 41-46, Jan–Mar 2024. | DOI: 10.4103/joc.joc_123_23
Kelsey L, Fleiss K, and Fleiss P. (2010). Methods in observational Epidemiology 2nd Edition, Statistical Methods for Rates and Proportion, formulas 3.18 and 19. Avaliable at: *Epi website (Open Source Statistics for Public Health): http://www.openepi.com/SampleSize/SSCohort.htm (reviewed on 27th November, 2015).
Xenidis N, Perraki M, Apostolaki S, et al. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer. 2013;108:549–556. doi: 10.1038/bjc.2012.597
Franken B, de Groot MR, Mastboom WJ, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14:R133. doi: 10.1186/bcr3333.
Bidard FC, Delaloge S, Giacchetti S, et al. Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study [abstract] Cancer Res. 2012;72(24 Suppl) Abstract P2-01-04.
Gupta, R., Gupta, S., Antonios, B., Ghimire, B., Jindal, V., Deol, J., ... & Jaiyesimi, I. (2022). Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Medical Oncology, 39(12), 258.
Costanza Paoletti, Maria C. Muñiz, Dafydd G. Thomas, Kent A. Griffith, Kelley M. Kidwell, Nahomi Tokudome, Martha E. Brown, Kimberly Aung, M. Craig Miller, Dorothy L. Blossom, Anne F. Schott, N. Lynn Henry, James M. Rae, Mark C. Connelly, David A. Chianese, Daniel F. Hayes; Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer. Clin Cancer Res 1 June 2015; 21 (11): 2487–2498. https://doi.org/10.1158/1078-0432.CCR-14-1913
Nitta, H., Kelly, B. D., Allred, C., Jewell, S., Banks, P., Dennis, E., & Grogan, T. M. (2016). The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathology international, 66(6), 313-324. https://doi.org/10.1111/pin.12407
Xu, L., Xie, Y., Gou, Q., Cai, R., Bao, R., Huang, Y., & Tang, R. (2024). HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future. Frontiers in pharmacology, 15, 1446414. https://doi.org/10.3389/fphar.2024.1446414
Jagosky, M., & Tan, A. R. (2021). Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast cancer (Dove Medical Press), 13, 393–407. https://doi.org/10.2147/BCTT.S176514
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
